ArticleMicrobiology spectrum2025
O-GlcNAcylation at S659 enhances SARS-CoV-2 spike protein stability and pseudoparticle packaging efficiency.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- O-GlcNAcylation licenses RNF166 to degrade the M protein of porcine coronaviruses.PLoS pathogens · 2026Article
- O-GlcNAcylation: A Nutrient-Sensitive Metabolic Rheostat in Antiviral Immunity and Viral Pathogenesis.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a crucial role in viral entry and pathogenesis, making it an important target for therapeutic strategies. In this study, we explore the interaction between the S protein and O-GlcNAc transferase (OGT), revealing a physical association between these proteins using immunoprecipitation and glutathione-S-transferase (GST)-pulldown assays. Our results demonstrate that Serine 659 (S659) is the primary site of O-GlcNAcylation on the S protein, as confirmed by ion mobility mass spectrometry and mutagenesis studies. Notably, the S659A mutation significantly reduces O-GlcNAcylation of the S protein, leading to increased ubiquitination and subsequent degradation of the S protein. Cycloheximide pulse-chase assays further corroborate that the wild-type S protein exhibits greater stability compared with the S659A mutant of S. Despite these stability changes, the S659A mutation does not impair the binding affinity of the S protein to its receptor ACE2. However, we find that the S659A mutation significantly decreases the packaging efficiency of SARS-CoV-2 pseudoparticles. Collectively, our findings highlight the critical role of O-GlcNAcylation at S659 in regulating S protein stability and viral particle assembly, underscoring its potential as a target for therapeutic intervention against SARS-CoV-2. IMPORTANCE: This study highlights the critical role of the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the viral infection process and its potential as a target for therapies and vaccines. By identifying Serine 659 (S659) as a key site for O-GlcNAcylation, the research reveals how modifications at this residue can influence the protein's interactions with host factors, thereby affecting viral replication and pathogenicity. Furthermore, the S659A mutation was shown to lead to a significant increase in ubiquitination and degradation of the S protein, indicating that O-GlcNAcylation is crucial for modulating the protein's stability and, consequently, its efficiency in facilitating viral entry. Understanding these mechanisms is vital for the development of effective interventions against coronavirus disease 2019 (COVID-19). Overall, this research enhances our understanding of how post-translational modifications impact viral behavior, opening avenues for innovative strategies to combat SARS-CoV-2 and future viral threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.